Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
A 10-member commission told city leaders to turn the defunct 115-acre General Motors metal stamping plant site into a hip, funky neighborhood with an eye-catching bridge across the White River for easy access to downtown.
Eli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval in Europe, putting the drug on track to enter the region’s market this year.
The city plans to tap a taxing district downtown to help pay for the Bush Stadium renovation, rekindling concern among some elected officials and taxing experts that the Mayor’s Office is using the massive district to fund whatever special city needs crop up.
The recently announced 16 Tech District adds a new tool to Indianapolis’ strong life sciences arsenal.
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
The North of South mixed-use project in downtown Indianapolis is just the latest development for Brad Chambers, who started out in the landscaping business.
A total of 220 life sciences startups have been launched in Indiana since 2004, or an average of 44 per year, according to a new report from BioCrossroads that tracked the industry’s growth over the last eight years.
European Union regulators have approved the first once-per-week diabetes medication, the companies that developed the drug said Tuesday.
Say what? “Excessive hospitality” while promoting its drug Byetta got Eli Lilly and Co. dinged by the U.K.-based Prescription Medicines Code of Practice Authority, a self-regulatory group. And what exactly counts as “excessive”? Seven pints of beer, two gins, two whiskies, seven whisky liqueurs and three large glasses of red wine—oh, and a taxi fare afterward, according to a summary of the case posted by the practice authority. The booze was purchased at an Indian restaurant for three Lilly sales reps and two diabetes nursing specialists. The occasion was the endocrinologist speaking about off-label uses of Byetta. The practice authority asked Lilly to look into the complaints of an ex-employee, but Lilly said there was no case to answer. The authority determined otherwise, which is why it gave Lilly its public flogging.
Indiana University Health has pulled a prominent practice of cancer physicians into its fold. Central Indiana Cancer Centers sold its five facilities to IU Health and transferred its 150 employees to the Indianapolis-based hospital system. The 16 physicians in the practice will remain independent, but they have signed a service agreement with IU Health. Financial terms of the deal, which closed June 1, were not disclosed. But it is a big win for IU Health, as Central Indiana Cancer Centers has a well-established presence in Carmel, Fishers, Greenfield, Greenwood and the east side of Indianapolis. Cancer services are key financially for hospitals because of the growing prevalence of the disease, and also because cancer patients often need surgery. IU Health now has more than 60 medical oncologists, not counting any of its radiation oncologists or cancer surgeons. Central Indiana Cancer Centers, established near Community Hospital-East in 1976, also had discussions with the three other major hospital systems in Indianapolis: Community, St. Vincent Health and Franciscan St. Francis Health. A partnership with a hospital became essential for Central Indiana Cancer Centers as hospitals have spent the past three years gobbling up physicians of all stripes—both primary care doctors and specialists. IU Health Physicians now employs more than 500 doctors and Community Health Network has more than 550.
City officials on Thursday unveiled a long-term plan to redevelop an industrial stretch northwest of downtown with the goal of attracting hundreds of residents and dozens of high-tech companies to the area. The ambitious urban renewal effort, dubbed the 16 Downtown Technology District, builds from a strategy discussed over more than a decade to turn the corridor between IUPUI and 16th Street into a life-sciences research hub. The idea is to create a trendy urban district where residents can live within blocks of work. The project could require $15 million to $20 million in public investment and hundreds of millions of dollars in private investment. It is expected to take 10-20 years to complete. Officials said a final agreement is near for the redevelopment of the historic Bush Stadium site, which is wedged between 16th Street and the White River near Harding Street. The city is contributing about $5 million to the $23 million project, including tax dollars generated in the area and more that will be transferred from the consolidated downtown tax-increment financing district. Developer John Watson said he also is seeking a federal loan to help finance part of the project. Indianapolis also will invest another $3 million in public money to renovate Indiana Avenue from roughly 10th Street to 16th Street with new landscaping, walking paths, bike lanes and other streetscape elements designed to brand the area. That funding will come from initial proceeds from the sale of the city’s water and sewer utilities to Citizens Energy Group.
When I knew I was going to the exhibit opening, I was pleased because I’d heard so much about it, but I wasn’t expecting to emerge enthusiastically recommending it to just about everyone I talk to. Yet, that’s what happened.
Those who try to predict the future do not tell us their track records, but they do ask us to buy their books.
Eli Lilly and Co.'s lung cancer treatment Alimta is poised for continued growth based on recently released study data, according to a new Credit Suisse analyst report.
Corporations staged advances across a variety of industries in 2010 as the economy improved.
Despite enjoying rising revenues and profits, companies haven’t followed with big increases in job numbers.
Rolls-Royce Corp. this week was awarded a $34.2 million modification to an engine maintenance contract from the Department of Defense’s Naval Air Systems Command.
Aaron O'Mara, co-owner of Augustino's, expected to open several locales until the economic downturn and a dip in sales scuttled those plans. Now he hopes to hold the line.
Eli Lilly and Co. is getting into orthopedics. The Indianapolis-based drugmaker signed a deal with Swiss company Synthes Inc. to co-promote the bone drug Forteo to orthopedic surgeons and to license some experimental drugs to Synthes. The companies also will team up to study an additional use for Forteo in fracture healing. Terms of the deal were not disclosed. Synthes specializes in developing and selling instruments, implants and biomaterials to fix bone and soft tissues. It has agreed to sell itself to New Jersey-based Johnson & Johnson for $21 billion. In a separate development, Lilly won the first round in a court battle with another development partner, San Diego-based Amylin Pharmaceuticals Inc. A federal judge rejected Amylin’s claim that, if Lilly uses the same sales force to sell Byetta, a diabetes medicine made by Amylin, and Tradjenta, a diabetes pill made by Germany-based Boehringer Ingelheim GmbH, it would be anti-competitive. Amylin promised to appeal.
Three weeks after the CEO of Riley Hospital for Children resigned, his right-hand man announced his departure, too. Brett D. Lee, the chief operating officer at Riley, announced his plans June 8 to leave the Indianapolis hospital for a new job in Atlanta. His last day will be July 6. It’s not clear if Lee’s departure is connected to the May 20 resignation of Dan Fink, who had been CEO of Riley for about two years. Fink was replaced as CEO on an interim basis by Marilyn Cox, Riley’s chief nursing officer. Lee was considered a rising star at Riley, which is part of the Indianapolis-based Indiana University Health hospital system. Less than a year after being hired by Riley in April 2010, Lee was named the young health care executive of the year by the American College of Healthcare Executives, in part for his work applying Six Sigma and lean-process methods to the health care environment. Lee will become senior vice president of clinical operations at Children’s Healthcare of Atlanta, the nation’s largest provider of pediatric care. It has three free-standing hospitals, with a total of 520 beds, as well as 17 outpatient facilities throughout the Atlanta metro area.
Carmel-based Woll Enterprises Inc. has won a contract to commercialize three medical products invented by two Florida physicians. Dr. Nevenka Horvat and Dr. Branimir Horvat, of Sarasota, Fla., have developed a medication for relief from psoriasis and eczema; a placental blood extractor; and a sequential lymphedema pump for removing excess fluid from swollen limbs. Woll Enterprises will try to locate funding to move the products toward market approval.
Dow AgroSciences LLC announced a deal to purchase assets from Iowa-based Sansgaard Seed Farms Inc. Indianapolis-based Dow Agro will receive rights to Sansaard’s Praide Brand Seed brand, as well as other marketing assets, land, buildings and equipment. Sansgaard’s Iowa headquarters and staff will remain intact. But now Dow Agro will market its corn and soybean seeds under the Prairie Brand name. Dow has made several acquisitions of seed distributors in the past three years to build a distribution network for its SmartStax genetically engineered seed, as well as future innovations, like its Enlist Weed Control System for corn and soybeans. Financial terms of the agreement were not disclosed.
Nyhart, an Indianapolis-based actuarial and employee-benefits consulting firm, has acquired Atlanta-based Stanley, Holcombe & Associates, which focused on public pensions and defined-benefit retirement consulting. Financial details of the acquisition were not disclosed. Nyhart will keep the existing Atlanta office space as well as retain the entire Atlanta staff. The deal gives Nyhart a base of retirement clients that have more than $14 billion in plan assets.In December, Nyhart announced the purchase of the Kansas City, Mo., operations of retirement consultancy Alliance Benefit Group.
One thing that does stand out is that, on balance, these returns are not exactly going to get investors to sit up and get excited.
